Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robyn Warrener

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cell Cycle (Georgetown, Tex.)|August 4, 2011
Finally, how histone deacetylase inhibitors disrupt mitosis!Brian Gabrielli, KeeMing Chia, Robyn Warrener
Methods in Molecular Biology (Clifton, N.J.)|June 29, 2004
Analysis of checkpoint responses to histone deacetylase inhibitorsHeather Beamish, Robyn Warrener, Brian G Gabrielli
Annals of the New York Academy of Sciences|January 22, 2005
Defining the chemotherapeutic targets of histone deacetylase inhibitorsBrian Gabrielli, Robyn Warrener, Andrew Burgess, et al.
Molecular Pharmacology|June 22, 2010
Inhibition of histone deacetylase 3 produces mitotic defects independent of alterations in histone H3 lysine 9 acetylation and methylationRobyn Warrener, Keeming Chia, William D Warren, et al.
Oncogene|July 6, 2004
Histone deacetylase inhibitors specifically kill nonproliferating tumour cellsAndrew Burgess, Astrid Ruefli, Heather Beamish, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 26, 2003
Tumor cell-selective cytotoxicity by targeting cell cycle checkpointsRobyn Warrener, Heather Beamish, Andrew Burgess, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cell Cycle (Georgetown, Tex.)|August 4, 2011
Finally, how histone deacetylase inhibitors disrupt mitosis!Brian Gabrielli, KeeMing Chia, Robyn Warrener
Methods in Molecular Biology (Clifton, N.J.)|June 29, 2004
Analysis of checkpoint responses to histone deacetylase inhibitorsHeather Beamish, Robyn Warrener, Brian G Gabrielli
Annals of the New York Academy of Sciences|January 22, 2005
Defining the chemotherapeutic targets of histone deacetylase inhibitorsBrian Gabrielli, Robyn Warrener, Andrew Burgess, et al.
Molecular Pharmacology|June 22, 2010
Inhibition of histone deacetylase 3 produces mitotic defects independent of alterations in histone H3 lysine 9 acetylation and methylationRobyn Warrener, Keeming Chia, William D Warren, et al.
Oncogene|July 6, 2004
Histone deacetylase inhibitors specifically kill nonproliferating tumour cellsAndrew Burgess, Astrid Ruefli, Heather Beamish, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 26, 2003
Tumor cell-selective cytotoxicity by targeting cell cycle checkpointsRobyn Warrener, Heather Beamish, Andrew Burgess, et al.
Pageof 1